Showing results (21-30 of 34) with videos related to

Sort By:
Pageof 4
Movement Disorders : Official Journal of the Movement Disorder Society|March 22, 2016
Serum immune markers and disease progression in an incident Parkinson's disease cohort (ICICLE-PD)Caroline H Williams-Gray, Ruwani Wijeyekoon, Alison J Yarnall, et al.
Human Brain Mapping|January 14, 2017
Intra- and inter-network functional alterations in Parkinson's disease with mild cognitive impairmentLuis R Peraza, David Nesbitt, Rachael A Lawson, et al.
Journal of Neurology|April 27, 2018
Longitudinal diffusion tensor imaging changes in early Parkinson's disease: ICICLE-PD studyThais Minett, Li Su, Elijah Mak, et al.
Movement Disorders : Official Journal of the Movement Disorder Society|December 31, 2020
Cholinergic Basal Forebrain Volumes Predict Gait Decline in Parkinson's DiseaseJoanna Wilson, Alison J Yarnall, Chesney E Craig, et al.
Brain : a Journal of Neurology|July 16, 2015
Baseline and longitudinal grey matter changes in newly diagnosed Parkinson's disease: ICICLE-PD studyElijah Mak, Li Su, Guy B Williams, et al.
Neurobiology of Aging|April 22, 2017
Longitudinal whole-brain atrophy and ventricular enlargement in nondemented Parkinson's diseaseElijah Mak, Li Su, Guy B Williams, et al.
Brain : a Journal of Neurology|April 29, 2022
Free-water imaging of the cholinergic basal forebrain and pedunculopontine nucleus in Parkinson's diseaseNicola J Ray, Rachael A Lawson, Sarah L Martin, et al.
Brain : a Journal of Neurology|August 1, 2014
Genetic impact on cognition and brain function in newly diagnosed Parkinson's disease: ICICLE-PD studyCristina Nombela, James B Rowe, Sophie E Winder-Rhodes, et al.
Neurology|December 24, 2013
Characterizing mild cognitive impairment in incident Parkinson disease: the ICICLE-PD studyAlison J Yarnall, David P Breen, Gordon W Duncan, et al.
BMJ Open|May 29, 2021
Exenatide once weekly over 2 years as a potential disease-modifying treatment for Parkinson's disease: protocol for a multicentre, randomised, double blind, parallel group, placebo controlled, phase 3 trial: The 'Exenatide-PD3' studyNirosen Vijiaratnam, Christine Girges, Grace Auld, et al.
Pageof 4